GeneBioTech Co. ,Ltd (KOSDAQ:086060)
4,875.00
-10.00 (-0.20%)
At close: Apr 20, 2026
GeneBioTech Co. ,Ltd Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 9,587 | 10,279 | 8,751 | 7,430 | 7,430 |
Short-Term Investments | 15,310 | 13,125 | 13,265 | 8,660 | 10,360 |
Cash & Short-Term Investments | 24,897 | 23,404 | 22,016 | 16,090 | 17,790 |
Cash Growth | 6.38% | 6.31% | 36.83% | -9.56% | -35.04% |
Accounts Receivable | 12,388 | 13,364 | 11,588 | 14,090 | 10,225 |
Other Receivables | 265.33 | 356.36 | 180.69 | 183.82 | 74.85 |
Receivables | 12,982 | 14,053 | 11,818 | 14,302 | 10,371 |
Inventory | 14,074 | 17,041 | 14,802 | 15,452 | 13,676 |
Prepaid Expenses | 27.39 | 27.27 | 24.16 | 25.66 | 41.05 |
Other Current Assets | 2,730 | 1,310 | 621.38 | 399.76 | 298.05 |
Total Current Assets | 54,711 | 55,836 | 49,281 | 46,269 | 42,175 |
Property, Plant & Equipment | 16,972 | 13,924 | 14,159 | 14,615 | 14,900 |
Long-Term Investments | 2,406 | 639.43 | 718.86 | 484.19 | 763.6 |
Goodwill | - | - | - | 589.54 | 589.54 |
Other Intangible Assets | 582.66 | 648.82 | 632.02 | 398.29 | 199.07 |
Long-Term Deferred Tax Assets | 71.12 | 66.76 | 205.29 | 495.41 | 870.49 |
Other Long-Term Assets | 493.18 | 436.81 | 513 | 666.71 | 294.23 |
Total Assets | 75,634 | 71,988 | 66,017 | 64,041 | 60,368 |
Accounts Payable | 3,654 | 3,366 | 3,540 | 3,901 | 4,752 |
Accrued Expenses | 1,160 | 1,077 | 970.5 | 649.23 | 515.74 |
Short-Term Debt | 8,109 | 10,851 | 7,704 | 9,486 | 8,042 |
Current Portion of Long-Term Debt | 1,924 | 2,359 | 1,534 | 1,159 | - |
Current Portion of Leases | 76.19 | 95.17 | 132.92 | 42.29 | 112.39 |
Current Income Taxes Payable | 413.78 | 278.37 | 284.27 | 14.46 | - |
Other Current Liabilities | 377.37 | 337.78 | 347.33 | 667.94 | 716.5 |
Total Current Liabilities | 15,715 | 18,364 | 14,513 | 15,920 | 14,139 |
Long-Term Debt | 4,782 | 2,466 | 2,995 | 2,329 | 2,113 |
Long-Term Leases | 66.38 | 113.47 | 135.08 | 12.35 | 33.57 |
Other Long-Term Liabilities | 74.68 | 72.07 | 68.54 | 53.02 | 137 |
Total Liabilities | 20,638 | 21,016 | 17,712 | 18,315 | 16,423 |
Common Stock | 4,305 | 4,305 | 4,305 | 4,305 | 4,305 |
Additional Paid-In Capital | 14,576 | 14,576 | 14,576 | 14,576 | 14,489 |
Retained Earnings | 35,889 | 31,803 | 29,059 | 18,116 | 16,190 |
Comprehensive Income & Other | 225.65 | 288.42 | 364.07 | 8,729 | 8,961 |
Total Common Equity | 54,996 | 50,972 | 48,305 | 45,726 | 43,945 |
Shareholders' Equity | 54,996 | 50,972 | 48,305 | 45,726 | 43,945 |
Total Liabilities & Equity | 75,634 | 71,988 | 66,017 | 64,041 | 60,368 |
Total Debt | 14,957 | 15,885 | 12,502 | 13,029 | 10,302 |
Net Cash (Debt) | 9,940 | 7,519 | 9,514 | 3,061 | 7,488 |
Net Cash Growth | 32.20% | -20.97% | 210.80% | -59.12% | -65.62% |
Net Cash Per Share | 1154.33 | 873.87 | 1104.91 | 355.50 | 869.68 |
Filing Date Shares Outstanding | 8.61 | 8.61 | 8.61 | 8.61 | 8.61 |
Total Common Shares Outstanding | 8.61 | 8.61 | 8.61 | 8.61 | 8.61 |
Working Capital | 38,996 | 37,472 | 34,768 | 30,349 | 28,037 |
Book Value Per Share | 6385.98 | 5919.73 | 5609.93 | 5310.44 | 5103.62 |
Tangible Book Value | 54,413 | 50,323 | 47,673 | 44,738 | 43,157 |
Tangible Book Value Per Share | 6318.32 | 5844.37 | 5536.52 | 5195.72 | 5012.04 |
Land | 7,011 | 7,011 | 7,061 | 5,464 | 5,464 |
Buildings | 10,084 | 6,452 | 6,533 | 6,489 | 6,471 |
Machinery | 10,097 | 9,547 | 9,342 | 9,255 | 9,222 |
Construction In Progress | 540 | 595.13 | 41.65 | 1,620 | 1,007 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.